<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947319</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-4059-09</org_study_id>
    <nct_id>NCT04947319</nct_id>
  </id_info>
  <brief_title>Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)</brief_title>
  <official_title>An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib in&#xD;
      patients with relapsed or refractory PCNSL&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>Overall response rate is defined as the proportion of patients with a best overall response of Complete response (CR), Complete response - unconfirmed (CRu), or (=partial response (PR) as determined by an independent review committee according to the International PCNSL Collaborative Group (IPCG) criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2 year</time_frame>
    <description>Duration of response is defined as the time between the date of first response (CR, CRu, or PR) and the date of the first PD according to the IPCG criteria, or date of death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>1 year</time_frame>
    <description>Time to response is defined as the time between the date of first administration of tirabrutinib and the date of first response (CR, CRu, or PR) as determined by IRC according to the IPCG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>1 year</time_frame>
    <description>Best overall response based on IRC response determination is defined as the best response and is derived programmatically based upon the visit responses determined by IRC from the date of administration of tirabrutinib to the date of PD as determined by IRC or the date of initiation of subsequent anticancer therapy for PCNSL, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in corticosteroid dose</measure>
    <time_frame>2 year</time_frame>
    <description>Descriptive statistics will be calculated for the actual corticosteroid dose and the change from baseline at each assessment point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AEs and SAEs</measure>
    <time_frame>2 year</time_frame>
    <description>Adverse events at each visit with the NCI CTCAE v5.0 used as a guide for the grading of severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory abnormality profile of tirabrutinib as measured by incidence and severity of clinical laboratory abnormalitiesclinical laboratory abnormalities</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG parameters by 12 lead ECG</measure>
    <time_frame>2 years</time_frame>
    <description>Heart rate, RR and QT intervals, QTc (QTcF, QTcB), PR interval, and QRS width.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters (Cmax) of tirabrutinib in the plasma</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters (Tmax) of tirabrutinib in the plasma</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters (AUC) of tirabrutinib in the plasma</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)</condition>
  <arm_group>
    <arm_group_label>Tirabrutinib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirabrutinib</intervention_name>
    <description>Tirabrutinib 480 mg, taken orally, once a day on an empty stomach. Tirabrutinib treatment may be continued until disease progression or clinically unacceptable toxicity is observed.</description>
    <arm_group_label>Tirabrutinib monotherapy</arm_group_label>
    <other_name>ONO-4059</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent by the patient prior to screening&#xD;
&#xD;
          2. Patients aged â‰¥ 18 years on the day of consenting to the study&#xD;
&#xD;
          3. Pathologic diagnosis of PCNSL&#xD;
&#xD;
          4. Relapse or refractory PCNSL with at least one prior HD MTX based therapy for PCNSL&#xD;
&#xD;
          5. Measurable brain lesion with a minimum diameter &gt; 1.0 cm in gadolinium enhanced&#xD;
             magnetic resonance imaging (MRI) performed within 14 days before starting tirabrutinib&#xD;
             treatment&#xD;
&#xD;
          6. ECOG PS of 0, 1 or 2&#xD;
&#xD;
          7. Life expectancy of at least 3 months&#xD;
&#xD;
          8. Adequate bone marrow, renal, and hepatic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intraocular PCNSL with no brain lesion&#xD;
&#xD;
          2. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to&#xD;
             contrast agents&#xD;
&#xD;
          3. Patient with non-B cell PCNSL&#xD;
&#xD;
          4. Patient with systemic presence of lymphoma&#xD;
&#xD;
          5. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with&#xD;
             anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14&#xD;
             days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant&#xD;
             within 6 months before starting tirabrutinib treatment&#xD;
&#xD;
          6. Prior BTK inhibitor treatment&#xD;
&#xD;
          7. Prior investigational drugs (including treatment in clinical research, unapproved&#xD;
             combination products, and new dosage forms) within 28 days or 5 half-lives, whichever&#xD;
             is shorter, before starting tirabrutinib treatment&#xD;
&#xD;
          8. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting&#xD;
             tirabrutinib treatment, with the exception of the following:&#xD;
&#xD;
               -  Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL&#xD;
&#xD;
               -  Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone)&#xD;
                  for patients with lesions of the brain or spinal cord or both&#xD;
&#xD;
          9. Patient who has received a CYP3A4 inducer or P gp inducer within 14 days before&#xD;
             starting tirabrutinib treatment&#xD;
&#xD;
         10. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K&#xD;
             antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis&#xD;
             within 7 days before starting tirabrutinib treatment&#xD;
&#xD;
         11. Active malignancy, other than PCNSL requiring systemic therapy&#xD;
&#xD;
         12. Poorly controlled comorbidity, severe heart, severe lung disease, clinically&#xD;
             significant liver diseases that could affect protocol compliance or safety or efficacy&#xD;
             assessments&#xD;
&#xD;
         13. Patient with bleeding diathesis&#xD;
&#xD;
         14. Patients with a history of moderate or severe hepatic impairment&#xD;
&#xD;
         15. QTcF &gt; 480 milliseconds or requirement for ongoing treatment with concomitant&#xD;
             medications that prolong the QT interval&#xD;
&#xD;
         16. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has&#xD;
             had, within 28 days before starting tirabrutinib treatment, an infection (other than&#xD;
             nail trichophytosis) that requires hospitalization or an intravenous antibiotic&#xD;
&#xD;
         17. Prior history of hypersensitivity or anaphylaxis to tirabrutinib&#xD;
&#xD;
         18. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis&#xD;
&#xD;
         19. Medical history of organ allografts&#xD;
&#xD;
         20. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1&#xD;
             antibody, HBs antigen, or HCV antibody. Tests positive for HBs antibody or hepatitis B&#xD;
             virus core protein antibody and has a result of at least detectable in a hepatitis B&#xD;
             virus deoxyribonucleic acid assay despite testing negative for HBs antigen.&#xD;
&#xD;
         21. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a&#xD;
             comorbidity that affects gastric function; has undergone complete resection of the&#xD;
             stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel&#xD;
             disease; or has partial or complete intestinal obstruction.&#xD;
&#xD;
         22. Women who are pregnant or lactating&#xD;
&#xD;
         23. Patient is found incapable of giving consent due to dementia or another such condition&#xD;
&#xD;
        18. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis 19. Medical&#xD;
        history of organ allografts 20. Tests positive for HIV-1 antibody and HIV-2 antibody, human&#xD;
        T-lymphotropic virus 1 antibody, HBs antigen, or HCV antibody. Tests positive for HBs&#xD;
        antibody or hepatitis B virus core protein antibody and has a result of at least detectable&#xD;
        in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs&#xD;
        antigen.&#xD;
&#xD;
        21. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a&#xD;
        comorbidity that affects gastric function; has undergone complete resection of the stomach&#xD;
        or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or&#xD;
        has partial or complete intestinal obstruction.&#xD;
&#xD;
        22. Women who are pregnant or lactating 23. Patient is found incapable of giving consent&#xD;
        due to dementia or another such condition 24. Patient is found to be otherwise ineligible&#xD;
        for the study by the Investigator or sub-Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arata Aoi</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharma USA Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ono Pharmaceutical Co. Ltd Medical Information Center</last_name>
    <email>clinical_trial@ono.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedar Sinai Medical Cancer</name>
      <address>
        <city>Hollywood</city>
        <state>California</state>
        <zip>90046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University, Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University - Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - St. Matthews</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute - Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>41809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center (KUCC) (Kansas City Cancer Center (KCCC)) - North</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center - John Theurer Cancer</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University, Center for Health and Healing 2</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Bone and Joint Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University and Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Cancer Institute</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>27920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Utah - Huntsman Cancer Institute (HCI)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Vermont - Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton's Tyrosine Kinase (BTK) Inhibitor, tirabrutinib, ONO-4059, PROSPECT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_url>https://www.ono.co.jp/eng/rd/policy.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

